Scarica l'app Stockscreener
8.375
10.43%
-0.975
Dopo l'orario di chiusura:
8.53
0.155
+1.85%
Precedente Chiudi:
$9.35
Aprire:
$8.94
Volume 24 ore:
1.64M
Relative Volume:
1.11
Capitalizzazione di mercato:
$743.74M
Reddito:
$73.48M
Utile/perdita netta:
$-108.30M
Rapporto P/E:
-3.7222
EPS:
-2.25
Flusso di cassa netto:
$-67.17M
1 W Prestazione:
+5.21%
1M Prestazione:
-14.71%
6M Prestazione:
+22.08%
1 anno Prestazione:
+49.55%
Intervallo 1D:
$8.11
$9.0236
Intervallo di 1 settimana:
$7.7201
$9.74
Portata 52W:
$2.8262
$11.40
Personalis Inc Stock (PSNL) Company Profile
Nome
Personalis Inc
Settore
Industria
Telefono
650-752-1300
Indirizzo
6600 DUMBARTON CIRCLE, FREMONT, CA
Confronta PSNL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.375 | 830.32M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
606.50 | 231.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.00 | 166.39B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
712.39 | 57.06B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
243.19 | 41.60B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
145.76 | 41.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Iniziato | Guggenheim | Buy |
| 2025-03-17 | Iniziato | Craig Hallum | Buy |
| 2023-02-06 | Aggiornamento | Needham | Hold → Buy |
| 2022-01-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Downgrade | Needham | Buy → Hold |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-20 | Reiterato | Needham | Buy |
| 2021-05-06 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-12 | Reiterato | Needham | Buy |
| 2020-11-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2019-09-26 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Iniziato | BofA/Merrill | Neutral |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Morgan Stanley | Overweight |
| 2019-07-15 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Personalis Inc Borsa (PSNL) Ultime notizie
Can Personalis Inc. stock outperform in 2025 bull marketGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Is Personalis Inc. stock a buy for dividend growth2025 Macro Impact & Real-Time Chart Breakout Alerts - ulpravda.ru
Why Personalis Inc. stock remains a top recommendationJuly 2025 Market Mood & Risk Controlled Stock Alerts - ulpravda.ru
Will Personalis Inc. stock remain a Wall Street favoriteQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - ulpravda.ru
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace
PSNL Achieves Key Medicare Coverage Milestone for Breast Cancer - GuruFocus
Personalis (PSNL) Achieves Remarkable Growth in Clinical Volumes - GuruFocus
Personalis reports select preliminary fourth quarter and full year 2025 results - MarketScreener
Institutional Investors Are Personalis, Inc.'s (NASDAQ:PSNL) Biggest Bettors and Were Rewarded After Last Week's US$105m Market Cap Gain - 富途牛牛
Personalis (NASDAQ:PSNL) delivers shareholders splendid 54% CAGR over 3 years, surging 15% in the last week alone - simplywall.st
Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Will Personalis Inc stock remain a Wall Street favoriteJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - moha.gov.vn
Quant Funds Rotate Into Pavna Industries Limited StockTechnical Analysis Insights & Stay Invested. Stay Smart. - earlytimes.in
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) - Insider Monkey
Personalis Outpaces The Market With Cancer Test Breakthroughs - Finimize
Would You Still Hold Personalis Stock If It Fell Another 30%? - Trefis
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Personalis Inc. (04X) stock split increase liquidityRate Cut & Entry and Exit Point Strategies - Улправда
How Personalis Inc. stock reacts to bond yieldsWeekly Trading Summary & Safe Entry Point Alerts - ulpravda.ru
Is Personalis Inc. stock attractive for hedge funds2025 Bull vs Bear & Community Consensus Trade Signals - Улправда
Personalis (NASDAQ:PSNL) Sees Strong Trading VolumeHere's Why - MarketBeat
Nasdaq Moves: How Personalis Inc. stock reacts to bond yieldsWeekly Stock Recap & Reliable Price Action Trade Plans - ulpravda.ru
Aug Opening: How risky is Personalis Inc. stock nowTrade Exit Summary & Daily Price Action Insights - Улправда
Revenue Check: Will Personalis Inc. (04X) stock split increase liquidityJuly 2025 Price Swings & Daily Price Action Insights - Улправда
How risky is Personalis Inc. stock nowJuly 2025 Earnings & Safe Investment Capital Preservation Plans - Улправда
Personalis study shows cancer blood test predicts immunotherapy outcomes By Investing.com - Investing.com Nigeria
Personalis study shows cancer blood test predicts immunotherapy outcomes - Investing.com
Personalis announces new publication applying ultrasensitive ctDNA testing - marketscreener.com
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors - Business Wire
About Us - FinancialContent
Personalis (NASDAQ:PSNL) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer - Business Wire
Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds - Yahoo Finance
Personalis, Inc. $PSNL Shares Purchased by Blue Water Life Science Advisors LP - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 38% But Its P/S Still Looks Reasonable - 富途牛牛
Personalis (NASDAQ:PSNL) Stock Price Down 4.8%What's Next? - MarketBeat
Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen - MarketBeat
Is Personalis Inc. (04X) stock undervalued by metricsEarnings Miss & Short-Term High Return Strategies - Newser
Geode Capital Management LLC Buys 851,422 Shares of Personalis, Inc. $PSNL - MarketBeat
Will Personalis Inc. (04X) stock maintain strong growthWeekly Volume Report & Growth Focused Investment Plans - Newser
Will Personalis Inc. (04X) stock beat Nasdaq index returns2025 Short Interest & Real-Time Volume Spike Alerts - Newser
Will Personalis Inc. (04X) stock outperform Dow JonesMarket Risk Summary & Fast Moving Market Watchlists - Newser
Personalis Inc Azioni (PSNL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
2.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):